| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
110,895 |
48,995 |
$5.26M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
52,585 |
23,496 |
$2.99M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
30,945 |
13,887 |
$2.71M |
| 90832 |
Psychotherapy, 30 minutes with patient |
31,027 |
19,569 |
$1.22M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
26,273 |
15,351 |
$1.22M |
| 82075 |
|
50,871 |
19,688 |
$1.17M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,950 |
8,627 |
$874K |
| 90837 |
Psychotherapy, 53 minutes with patient |
7,537 |
5,567 |
$677K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
1,770 |
885 |
$435K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14,452 |
9,125 |
$433K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
5,627 |
2,706 |
$421K |
| 80305 |
|
36,705 |
17,114 |
$276K |
| 99407 |
|
21,255 |
8,563 |
$208K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
6,056 |
4,053 |
$190K |
| 99401 |
|
4,704 |
3,514 |
$157K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,917 |
2,526 |
$125K |
| 90834 |
Psychotherapy, 45 minutes with patient |
2,324 |
1,788 |
$122K |
| 99406 |
|
4,665 |
3,179 |
$121K |
| 99205 |
Prolong outpt/office vis |
1,725 |
1,170 |
$121K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,346 |
2,894 |
$102K |
| 99408 |
|
16,605 |
6,180 |
$92K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,186 |
869 |
$77K |
| 99385 |
|
1,649 |
1,268 |
$68K |
| 90791 |
Psychiatric diagnostic evaluation |
1,100 |
1,035 |
$61K |
| Q3014 |
Telehealth originating site facility fee |
4,217 |
3,321 |
$61K |
| 99386 |
|
1,444 |
1,107 |
$58K |
| 81025 |
|
2,152 |
1,609 |
$54K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,733 |
3,723 |
$46K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
432 |
357 |
$38K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
337 |
297 |
$32K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
296 |
255 |
$18K |
| H0031 |
Mental health assessment, by non-physician |
267 |
256 |
$13K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
409 |
280 |
$12K |
| 93000 |
|
1,598 |
1,119 |
$11K |
| 76942 |
|
40 |
39 |
$9K |
| 96127 |
|
3,632 |
1,878 |
$8K |
| 99215 |
Prolong outpt/office vis |
84 |
67 |
$7K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
5,568 |
2,960 |
$7K |
| 80306 |
|
2,048 |
1,067 |
$7K |
| 86328 |
|
298 |
184 |
$6K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
383 |
239 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
112 |
103 |
$3K |
| 99442 |
|
5,896 |
2,772 |
$3K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
2,497 |
1,432 |
$2K |
| 99345 |
Prolong home eval add 15m |
62 |
61 |
$2K |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
477 |
177 |
$2K |
| 99348 |
|
101 |
78 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
1,066 |
677 |
$1K |
| 99347 |
|
129 |
88 |
$705.90 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
51 |
33 |
$628.90 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
45 |
39 |
$547.21 |
| 99441 |
|
963 |
834 |
$416.30 |
| G0397 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes |
16 |
13 |
$372.17 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
56 |
41 |
$198.47 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
1,096 |
709 |
$187.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
18 |
14 |
$123.48 |
| 81003 |
|
116 |
84 |
$67.76 |
| 82962 |
|
16 |
16 |
$36.45 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
24 |
16 |
$31.48 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
104 |
71 |
$9.58 |
| 99443 |
|
43 |
31 |
$0.00 |
| J3490 |
Unclassified drugs |
50 |
47 |
$0.00 |
| 99358 |
Prolong nursin fac eval 15m |
135 |
98 |
$0.00 |
| 80354 |
|
2,194 |
1,126 |
$0.00 |
| 98960 |
|
1,227 |
762 |
$0.00 |
| 99483 |
Prolong outpt/office vis |
95 |
52 |
$0.00 |
| J0735 |
Injection, clonidine hydrochloride, 1 mg |
15 |
12 |
$0.00 |